
Medpace Holdings MEDP
$ 599.7
0.79%
Quarterly report 2025-Q3
added 10-23-2025
Medpace Holdings Total Current Liabilities 2011-2026 | MEDP
Annual Total Current Liabilities Medpace Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.1 B | 925 M | 803 M | 557 M | 440 M | 343 M | 257 M | 193 M | 169 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.1 B | 169 M | 532 M |
Total Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
169 M | - | -17.87 % | $ 25.9 M | ||
|
Chembio Diagnostics
CEMI
|
39.3 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
1.81 M | - | - | $ 9.42 M | ||
|
Burning Rock Biotech Limited
BNR
|
372 M | $ 23.41 | 0.47 % | $ 252 M | ||
|
Biocept
BIOC
|
5.51 M | - | -13.05 % | $ 7.29 M | ||
|
Castle Biosciences
CSTL
|
49.4 M | $ 39.7 | 0.92 % | $ 1.1 B | ||
|
Co-Diagnostics
CODX
|
5.75 M | $ 6.0 | -3.07 % | $ 176 M | ||
|
Accelerate Diagnostics
AXDX
|
66.6 M | - | -61.36 % | $ 2.46 M | ||
|
DermTech
DMTK
|
13.4 M | - | -11.32 % | $ 2.94 M | ||
|
DexCom
DXCM
|
1.56 B | $ 70.68 | 4.87 % | $ 27.3 B | ||
|
BioNano Genomics
BNGO
|
37.3 M | $ 1.58 | - | $ 2.01 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
13.8 M | - | - | $ 562 M | ||
|
Guardant Health
GH
|
226 M | $ 107.76 | -2.19 % | $ 13.2 B | ||
|
Global Cord Blood Corporation
CO
|
647 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.27 B | - | - | $ 10.7 B | ||
|
Illumina
ILMN
|
1.55 B | $ 145.25 | 2.96 % | $ 23.1 B | ||
|
IQVIA Holdings
IQV
|
6.96 B | $ 241.11 | -0.55 % | $ 43.7 B | ||
|
CareDx, Inc
CDNA
|
78.1 M | $ 20.41 | 19.15 % | $ 1.1 B | ||
|
Danaher Corporation
DHR
|
6.8 B | $ 238.83 | 0.2 % | $ 175 B | ||
|
Celcuity
CELC
|
31.7 M | $ 104.34 | -2.95 % | $ 4.12 B | ||
|
DarioHealth Corp.
DRIO
|
12.5 M | $ 11.97 | -1.56 % | $ 340 M | ||
|
Anixa Biosciences
ANIX
|
1.97 M | $ 3.19 | -5.62 % | $ 102 K | ||
|
Enzo Biochem
ENZ
|
24.8 M | - | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
241 M | $ 67.28 | -0.41 % | $ 4.66 B | ||
|
Exact Sciences Corporation
EXAS
|
732 M | $ 102.23 | 0.11 % | $ 18.9 B | ||
|
Fulgent Genetics
FLGT
|
72.9 M | $ 28.16 | 1.11 % | $ 851 M | ||
|
Aspira Women's Health
AWH
|
5.78 M | - | -6.19 % | $ 10.5 M | ||
|
Motus GI Holdings
MOTS
|
3.27 M | - | -34.28 % | $ 263 K | ||
|
Myriad Genetics
MYGN
|
164 M | $ 6.56 | -0.3 % | $ 594 M | ||
|
Charles River Laboratories International
CRL
|
994 M | $ 219.73 | -0.62 % | $ 11.3 B | ||
|
Heska Corporation
HSKA
|
39.6 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
8.27 M | - | -20.0 % | $ 1.06 M | ||
|
National Research Corporation
NRC
|
36.2 M | $ 20.3 | 2.94 % | $ 498 M | ||
|
Mettler-Toledo International
MTD
|
1.17 B | $ 1 486.95 | 0.1 % | $ 31.6 B | ||
|
Natera
NTRA
|
310 M | $ 233.65 | -0.28 % | $ 23 B | ||
|
ENDRA Life Sciences
NDRA
|
605 K | $ 4.51 | -3.01 % | $ 2.42 M | ||
|
Invitae Corporation
NVTA
|
108 M | - | - | $ 21.2 M | ||
|
Neogen Corporation
NEOG
|
174 M | $ 9.33 | -3.01 % | $ 2.02 B | ||
|
Quest Diagnostics Incorporated
DGX
|
2.17 B | $ 175.05 | 0.34 % | $ 19.4 B | ||
|
Biodesix
BDSX
|
14.3 M | $ 8.2 | 50.18 % | $ 1.06 B | ||
|
Organovo Holdings
ONVO
|
3.74 M | - | -2.3 % | $ 19.4 M | ||
|
Laboratory Corporation of America Holdings
LH
|
3.33 B | $ 249.91 | -0.75 % | $ 21 B | ||
|
ICON Public Limited Company
ICLR
|
2.8 B | $ 180.43 | -0.52 % | $ 14.9 B | ||
|
IDEXX Laboratories
IDXX
|
1.07 B | $ 722.17 | 1.24 % | $ 59.6 B |